Randomized phase II study comparing induction chemotherapy combining cisplatin, 5-Fluorouracil and docetaxel at modified doses (TPFm) or standard doses (TPF) in patients with locally advanced squamous cell ENT cancer
Coordinator : Dr Fayette
Start date : not started September 2020
Number of patients : 167
Access detailed information on the trial in the private section
A phase II trial evaluating radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck
Coordinator : Prof. BOURHIS
Start date : 2019
Number of patients : 73
Access detailed information on the trial in the private section
Phase III randomized trial of post-operative adjuvant nivolumab and concomitant cisplatin-radiotherapy (standard of care) in patients with locally advanced resected squamous cell carcinoma of the head and neck (SCCHN) at high risk of recurrence
Coordinator : Prof. BOURHIS
Start date : 2018
Number of patients : 484 (242 per arm)
Access detailed information on the trial in the private section
Multicenter, prospective, single-arm phase II study evaluating the efficacy and safety of Durvalumab with Carboplatin and Paclitaxel as first-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck not eligible for standard chemotherapy
Coordinator : Dr Fayette
Start date : 2019
Number of patients : 102
Access detailed information on the trial in the private section
STEREO-POSTOP (GORTEC 2017-03)
Trial closed to inclusions
Multicenter, phase II study of postoperative hypofractionated stereotactic radiotherapy in the treatment of localized oropharyngeal and oral cavity cancers with high risk margins
Coordinator : Dr Biau
Start date : 2018
Number of patients : 90
Access detailed information on the trial in the private section
Double-blind, multicenter, phase III study evaluating the efficacy of an oral immune modulating formula on survival during postoperative concomitant chemo-radiotherapy in head and neck squamous cell carcinoma
Coordinator : Dr Senesse
Start date : 2019
Number of patients : 306
Access detailed information on the trial in the private section
REACH (GORTEC 2017-01)
Trial closed to inclusions
Phase III randomized trial of avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous cell carcinoma of the head and neck
Coordinator : Prof. BOURHIS
Start date : 2017
Number of patients : 688
Access detailed information on the trial in the private section
Phase III randomized trial of chemo-radiotherapy versus radiotherapy alone in the treatment of sinus and salivary gland tumors
Coordinator : Dr François-Régis FERRAND
Start date : 2017
Number of patients : 260 (130/arm)
Access detailed information on the trial in the private section
PembroRad (GORTEC 2015-01)
Trial closed to inclusions
Phase II randomized study to determine the tolerance and efficacy of Pembrolizumab or Cetuximab combined with radiation therapy in patients with locally advanced squamous cell carcinoma of the head and neck.
Coordinator : Prof. BOURHIS
Start date : 2016
Number of patients : 132 patients (66 per arm)
Access detailed information on the trial in the private section
CisFRAD (GORTEC 2015-02)
Trial closed to inclusions
Phase II randomized study of RT cisplatin 100 versus weekly fractionated.
Coordinator : Dr Borel
Start date : 2016
Expected number of patients : 124
Access the Clinical Trials link
Access detailed information on the trial in the private section
Role of stereotactic radiotherapy in patients with oligometastases.
Coordinator : Prof. Sun
Start date : 2015
Expected number of patients : 78
Access the Clinical Trials link
Access detailed information on the trial in the private section
SALTORL study (GORTEC 2014-03)
Assessment of survival without laryngeal-esophageal dysfunction after 2 years in patients with resectable carcinoma of the larynx or hypopharynx.
Coordinator: Prof. Calais
Start date : 2015
Expected number of patients : 440
Access the Clinical Trials link
Access detailed information on the trial in the private section
RADAR study (GORTEC 2014-02)
Trial closed to inclusions
Observational study: preventive treatment of radiation dermatitis associated with radiotherapy + cetuximab.
Coordinator: Prof. Lartigau
Start date : 2015
Expected number of patients : 70
Access the Clinical Trials link
Access detailed information on the trial in the private section
Phase III trial evaluating the benefit of an oral immune modulating solution in the prevention of severe acute mucositis following chemotherapy
Coordinator : Dr SENESSE - Dr BOISSELIER
Start date : 2012
Number of patients 160
Access the Clinical Trials link
Access detailed information on the trial in the private section